流式细胞术检测ChAdOx1疫苗接种后VITT的血小板活化抗体
本研究针对ChAdOx1 nCov-19疫苗接种后罕见的疫苗诱导免疫性血栓性血小板减少症(VITT),开发了一种全血标准流式细胞术检测法,用于识别针对血小板因子4(PF4)的血小板活化抗体。该检测法简便易行,可使众多实验室快速诊断VITT。试验注册号NCT04370119。
要点
- VITT由针对PF4的血小板活化抗体引起。
- 全血流式细胞术可检测VITT相关致病抗体。
- 该法便于广泛开展,实现VITT快速诊断。
核心结论
- 全血标准流式细胞术可检测ChAdOx1 nCov-19疫苗接种后VITT相关的血小板活化抗体。
研究设计与样本
- 方法学研究,开发全血标准流式细胞术检测VITT致病抗体,试验注册号NCT04370119。
主要发现
- VITT是ChAdOx1 nCov-19疫苗接种后由抗PF4血小板活化抗体引起的罕见并发症。
- 所建立的流式细胞术可识别与VITT相关的致病抗体。
临床怎么用
- 该检测法简便易行,可帮助众多实验室快速诊断VITT。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccination is crucial in combatting the severe acute respiratory syndrome coronavirus 2 pandemic. The rare complication of thrombocytopenia and thrombotic complications at unusual sites after ChAdOx1 nCov-19 vaccination is caused by platelet-activating antibodies directed against platelet factor 4 (PF4). We present a widely applicable whole-blood standard flow cytometric assay to identify the pathogenic antibodies associated with vaccine-induced immune-mediated thrombotic thrombocytopenia (VITT) after ChAdOx1 nCov-19 vaccination. This assay will enable rapid diagnosis by many laboratories. This trial was registered at www.clinicaltrials.gov as #NCT04370119.
引用
- Handtke S, Wolff M, Zaninetti C, et al. A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination. Blood. 2021. PMID: 33945605. doi:10.1182/blood.2021012064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。